Loss of efficacy of biological therapies in psoriatic patients is a well-known event. Biological switching is common in clinical practice, especially in TNF-α and IL-12/23 inhibitors treatment1,2 . Recently, anti-IL-17A drugs such as secukinumab have provided a new therapeutic opportunity This article is protected by copyright. All rights reserved.

Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience

Stingeni, L
Conceptualization
;
2019

Abstract

Loss of efficacy of biological therapies in psoriatic patients is a well-known event. Biological switching is common in clinical practice, especially in TNF-α and IL-12/23 inhibitors treatment1,2 . Recently, anti-IL-17A drugs such as secukinumab have provided a new therapeutic opportunity This article is protected by copyright. All rights reserved.
2019
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11391/1447273
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 28
social impact